- Home
- ICCC vs ELEV Comparison
ICCC vs ELEV Comparison
Compare ICCC & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- ELEV
- Stock Information
- Founded
- ICCC 1982
- ELEV 2019
- Country
- ICCC United States
- ELEV United States
- Employees
- ICCC N/A
- ELEV N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- ICCC Health Care
- ELEV Health Care
- Exchange
- ICCC Nasdaq
- ELEV Nasdaq
- Market Cap
- ICCC 39.2M
- ELEV 37.6M
- IPO Year
- ICCC 1987
- ELEV 2021
- Fundamental
- Price
- ICCC $4.94
- ELEV $0.26
- Analyst Decision
- ICCC
- ELEV Buy
- Analyst Count
- ICCC 0
- ELEV 7
- Target Price
- ICCC N/A
- ELEV $3.78
- AVG Volume (30 Days)
- ICCC 10.9K
- ELEV 2.1M
- Earning Date
- ICCC 05-13-2025
- ELEV 03-06-2025
- Dividend Yield
- ICCC N/A
- ELEV N/A
- EPS Growth
- ICCC N/A
- ELEV N/A
- EPS
- ICCC N/A
- ELEV N/A
- Revenue
- ICCC $26,493,000.00
- ELEV N/A
- Revenue This Year
- ICCC N/A
- ELEV N/A
- Revenue Next Year
- ICCC N/A
- ELEV N/A
- P/E Ratio
- ICCC N/A
- ELEV N/A
- Revenue Growth
- ICCC 51.63
- ELEV N/A
- 52 Week Low
- ICCC $3.34
- ELEV $0.24
- 52 Week High
- ICCC $5.82
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- ICCC 48.48
- ELEV 22.62
- Support Level
- ICCC $4.56
- ELEV $0.24
- Resistance Level
- ICCC $5.05
- ELEV $0.27
- Average True Range (ATR)
- ICCC 0.23
- ELEV 0.04
- MACD
- ICCC 0.01
- ELEV -0.02
- Stochastic Oscillator
- ICCC 80.51
- ELEV 1.25
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.